Metastatic breast carcinomas display genomic and transcriptomic heterogeneity

Modern Pathology

Volumn 28, Issue 3, 2015, Pages 340-351

  Weigelt, Britta ^a   Ng, Charlotte K Y ^a   Shen, Ronglai ^a   Popova, Tatiana ^b   Schizas, Michail ^a   Natrajan, Rachael ^c   Mariani, Odette ^b   Stern, Marc Henri ^b,d   Norton, Larry ^a   Vincent Salomon, Anne ^b,d   Reis Filho, Jorge S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUT CURIE   (France)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; CLAUDIN; TUMOR MARKER;

ALLELE; ARTICLE; CANCER CLASSIFICATION; CLINICAL ARTICLE; COPY NUMBER VARIATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC HETEROGENEITY; GENOMICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SPINDLE CELL CARCINOMA; SQUAMOUS CELL METAPLASIA; TRANSCRIPTOMICS; TRIPLE NEGATIVE BREAST CANCER; TRIPLE NEGATIVE METAPLASTIC BREAST CARCINOMA; TUMOR CELL; CARCINOMA; DNA MICROARRAY; FEMALE; GENETICS; METAPLASIA; MIDDLE AGED; PATHOLOGY; PROCEDURES;

BIOMARKERS, TUMOR; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; METAPLASIA; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84938418752     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.142     Document Type: Article

References (36)

1. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167
2. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68
3. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-2767
4. Popova T, Manie E, Rieunier G, et al. Ploidy and largescale genomic instability consistently identify basallike breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012;72:5454-5462
5. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-352
6. Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012;30:1879-1887
7. Mayer IA, Abramson VG, Lehmann BD, et al. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res 2014;20:782-790
8. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-1948
9. Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 2013;19: 6380-6388
10. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014;232:142-150
11. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol 2010;4:192-208
12. Lakhani SR, Ellis IO, Schnitt SJ, et al. Special subtypes, In: WHO Classification of Tumours of the Breast, 4th edn. IARC Press: Lyon, 2012, pp 39-76
13. Weigelt B, Eberle C, Cowell CF, et al. Metaplastic breast carcinoma: more than a special type. Nat Rev Cancer 2014;14:147-148
14. Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 2006;17:605-613
15. McCarthy A, Savage K, Gabriel A, et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 2007;211:389-398
16. Molyneux G, Geyer FC, Magnay FA, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010;7:403-417
17. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basallike breast cancer. Proc Natl Acad Sci USA 2007;104: 12111-12116
18. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216: 141-150
19. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009;117:273-280
20. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009;69:4116-4124
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 1991;19:403-410
22. Marchio C, Iravani M, Natrajan R, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008;215:398-410
23. Tan DS, Lambros MB, Rayter S, et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009;15:2269-2280
24. Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010;220:562-573
25. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:413-421
26. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795
27. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013
28. Grigoriadis A, Mackay A, Noel E, et al. Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics 2012;13:619
29. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res 2010;38:e17
30. Popova T, Manie E, Stoppa-Lyonnet D, et al. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009;10:R128
31. Tse GM, Tan PH, Putti TC, et al. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol 2006;59:1079-1083
32. Sneige N, Yaziji H, Mandavilli SR, et al. Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. Am J Surg Pathol 2001;25:1009-1016
33. Gobbi H, Simpson JF, Borowsky A, et al. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer 1999;85:2170-2182
34. Dawson SJ, Rueda OM, Aparicio S, et al. A new genome-driven integrated classification of breast cancer and its implications. EMBO J 2013;32:617-628
35. Elloumi F, Hu Z, Li Y, et al. Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples. BMC Med Genomics 2011;4:54
36. Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triplenegative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-5540.